XALKORI in ALK+ advanced NSCLC: Efficacy in a real world setting
Dr Shobit Baijal explores the use of real world data to understand, in further detail, the use of Xalkori® in patients with ALK+ advanced NSCLC. He illustrates this by talking through a number of real world, retrospective, cohort study data that provides findings in support of sequential therapy with Xalkori®.
Dr Shobhit Baijal specialises in providing cutting edge, evidence-based cancer drug treatments and has a large clinical trial portfolio. He is the Clinical Lead for Oncology at the Heart of England NHS Trust and continues to actively treat cancer patients across all sites, as well as publishing papers and speaking at international cancer meetings.
1. Duruisseaux, M . et al., Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-302 CLINALK): a French nationwide cohort retrospective study. Oncotarget 2017, 8(18):21903-21917.
PP-XLK-GBR-0887. January 2019